Starting with Q three twenty twenty six sales results. Worldwide sales were twenty five point four billion dollars for the quarter, increasing six percent. Growth in the US was nine point one percent and one point eight percent outside the US. Acquisitions and divestitures had a net negative impact on worldwide growth of ten basis points. Now turning to earnings. ? For the quarter, net earnings were two hundred and ten million dollars and diluted earnings per share were nine cents versus two dollars and twelve cents a year ago. Results in the quarter were impacted by the proposed talc litigation resolution, as well as expenses associated with the Firefly Biotransaction and Sale Biomedicines collaboration, amounting to approximately $7 billion. Adjusted net earnings for the quarter were $6.3 billion, and adjusted diluted earnings per share were $2.59, representing a decrease of 6.8% and 7.5% respectively, compared to the third quarter of 2025. Adjusted earnings in the quarter were also impacted by expenses associated with the Firefly Biotransaction and Sale Biomedicines collaboration. I will now comment on business sales results in the quarter, focusing on the six key areas where meaningful innovation and strong commercial execution are driving our performance and fueling long-term growth. Beginning with innovative medicine, where our financial results reflect the depth of our expertise in innovation in areas of high unmet need across oncology, immunology, and neuroscience. Worldwide sales of $16.8 billion dollars increased seven point nine percent, which underscores the continued strength of our key brands and new launches. Growth in the U.S. was eleven point one percent and three percent outside the U.S. Divestitures had a negative impact of ten basis points on worldwide growth. In oncology, starting with multiple myeloma, DARZLEC's growth was fifteen point six percent, primarily driven by strong share gains of five points across all lines of therapy, with ten points in the frontline setting, as well as continued market growth, partially offset by OUS pricing headwinds. Pervicti achieved growth of 35.2%, driven by share gains across earlier lines of therapy and continued site expansion. TechVailey growth was 77.3%, driven by launch uptake and share gains across earlier lines of therapy following last quarter's approval in the U.S. ? for TechVailey plus Starzilex FastPro with U.S. growth greater than 100%. Talve growth was forty-two point one percent, driven by shear gains due to increased depth of prescribing in the community setting. In lung cancer, ribant plus last glues delivered growth of sixty-three point five percent, with strong share gains in the first and second lines driven by continued launch uptake in all regions, along with rapid uptake in Ribovant FastPro. ? In prostate cancer, Erlita delivered growth of 9.4%, with continued shear gains and market growth, partially offset by unfavorable patient mix. Within immunology, Trimfaya delivered impressive growth of 68.2%, driven by continued momentum from the IBD launch, with four points of share growth in both all sort of colitis and Crohn's disease, alongside continued market growth. Stellara declined 54%, which reflects continued competitive pressures from biosimilars and the ongoing shift towards novel classes. Growth in other immunology is driven by AMAVA and Icottide launch uptake in the US. ? In neuroscience, Spravato grew 36%, driven by continued share gains reflecting strong physician adoption and increased patient demand. Keplita showed significant growth of 66.1%, driven by strong continued launch momentum and adjunctive major depressive disorder and continued demand increases across bipolar disorder and schizophrenia. ? Now moving to MedTech. Worldwide sales of $8.6 billion increased 2.5%, with growth of 4.8% in the US and 0.1% outside the US. Overall cardiovascular grew 4.1%, including 20 basis points related to acquisitions. Electrophysiology delivered growth of 4.4%, driven by procedure expansion, commercial execution, and new product performance, partially offset by competitive PFA pressures which were more pronounced in ASPAC this quarter, as well as the lapping of prior year OUS inventory dynamics. ABIMED saw a decline of 1.5% due to lower patient volume. ? There are encouraging signals in the U.S. performance with improvement in the quarter, supported by acute myocardial infarction, cardiogenic shock, and impella 5.5 continuing to gain adoption. Shockwave grew double digits at 17.2%, driven by continued adoption of coronary and peripheral products as well as new product launches, and the reimbursement in the office based lab setting within the U.S. Surgery saw a decline of 1%, including a negative impact of approximately 30 basis points from divestitures. ? The decline is more notably driven by ongoing expansion of VBP in China, surgery transformation program outcomes across the portfolio, and Middle East disruption which impacted tender timing and ordering patterns. ? The decline was partially offset by portfolio strength, driven by recent innovations such as Ethicon 4000 and Dualto, as well as commercial execution and biosurgery. ? In Vision, growth was 5.1%, driven by premium innovation, strong execution, and global reach. Contact lenses and other products grew 4.3%, driven by strong performance in the Accuview OASIS one-day family of products, further solidifying our leadership position, partially offset by U.S. inventory dynamics. Surgical Vision delivered growth of 7.1%, driven by new product innovations, robust demand for premium IOLs, and strong commercial execution, partially offset by market specific factors such as disruptions in the Middle East. Orthopedics growth for the quarter was three point four percent, primarily driven by new product launches such as Volt and Trauma and Emphasis and HIPS, including strong commercial execution and vellus pull through and knees. ? Now turning to our consolidated statement of earnings for the third quarter of twenty twenty six. I'd like to highlight a few noteworthy items that have changed compared to the same quarter of last year. Cost of goods sold deleveraged by 150 basis points driven by unfavorable product sales mix and increased intangible asset amortization expense in the innovative medicine segment for intracellular, partially offset by the impact of tariff recoveries in the med tech business. Selling, marketing, and administrative expenses were flat as a percent of sales, reflecting consistent commercial investments in the innovative medicine business. We continue to invest strategically in research and development, deploying approximately 4.7 billion or 18.3% of sales, which includes $1 billion related to the acquisition of Firefly Bio. ? In process, research and development impairment costs of $339 million in the quarter is related to the write-off of Precardia, a non-core asset acquired as part of the broader ABIMED transaction. Other income and expense with a net expense of $5.8 billion as compared to $478 million of income in the third quarter of 2025, with the change primarily driven by the proposed talc litigation resolution and orthopedic separation related costs. The tax rate was a small net benefit in the quarter, primarily related to the positive tax effect associated with the accrual for the proposed TAC litigation resolution. More information can be found in our upcoming 10 Q for changes in taxes. Lastly, I'll direct your attention to the box section of the slide where we have also provided our income before tax, net earnings, and earnings per share adjusted to exclude the impact of intangible amortization expense and special items. ? Now let's look at the adjusted income before tax by segment for the quarter. Innovative medicine margin declined from 44.3% to 35.4%, primarily due to acquired in process research and development expense of approximately $1 billion related to the acquisition of Firefly Bio, transaction cost for sale biomedicine, and unfavorable product sales mix and cost of products sold. MedTech margin increased from 21% to 22.9%, driven by the impact of tariff recoveries, partially offset by increased strategic investments in commercial capabilities. As a result, adjusted income before tax for the enterprise, as a percentage of sales, decreased from 35.2% to 30.2%. This concludes the sales and earnings portion of the call, and I will now turn the call over to Joe.
Passages & reports (46) 14:57 Starting with Q three twenty twenty six sales results. Worldwide sales were twenty five po… Report 15:16 points. Now turning to earnings. Report 15:19 For Report 15:20 the quarter, net earnings were two hundred and ten million dollars and diluted earnings pe… Report 15:39 approximately $7 billion. Adjusted net earnings for the quarter were $6.3 billion, and adj… Report 15:59 expenses associated with the Firefly Biotransaction and Sale Biomedicines collaboration. I… Report 16:18 financial results reflect the depth of our expertise in innovation in areas of high unmet … Report 16:39 percent and three percent outside the U.S. Divestitures had a negative impact of ten basis… Report 16:59 setting, as well as continued market growth, partially offset by OUS pricing headwinds. Pe… Report 17:19 and share gains across earlier lines of therapy following last quarter's approval in the U… Report 17:23 for Report 17:23 TechVailey plus Starzilex FastPro with U.S. growth greater than 100%. Talve growth was for… Report 17:43 the first and second lines driven by continued launch uptake in all regions, along with ra… Report 17:51 In Report 17:51 prostate cancer, Erlita delivered growth of 9.4%, with continued shear gains and market gr… Report 18:11 colitis and Crohn's disease, alongside continued market growth. Stellara declined 54%, whi… Report 18:30 In Report 18:30 neuroscience, Spravato grew 36%, driven by continued share gains reflecting strong physici… Report 18:50 disorder and schizophrenia. Report 18:52 Now Report 18:52 moving to MedTech. Worldwide sales of $8.6 billion increased 2.5%, with growth of 4.8% in … Report 19:12 growth of 4.4%, driven by procedure expansion, commercial execution, and new product perfo… Report 19:32 patient volume. Report 19:33 There Report 19:33 are encouraging signals in the U.S. performance with improvement in the quarter, supported… Report 19:53 launches, and the reimbursement in the office based lab setting within the U.S. Surgery sa… Report 20:05 The Report 20:06 decline is more notably driven by ongoing expansion of VBP in China, surgery transformatio… Report 20:19 The Report 20:19 decline was partially offset by portfolio strength, driven by recent innovations such as E… Report 20:29 In Report 20:30 Vision, growth was 5.1%, driven by premium innovation, strong execution, and global reach.… Report 20:49 dynamics. Surgical Vision delivered growth of 7.1%, driven by new product innovations, rob… Report 21:09 by new product launches such as Volt and Trauma and Emphasis and HIPS, including strong co… Report 21:17 Now Report 21:17 turning to our consolidated statement of earnings for the third quarter of twenty twenty s… Report 21:36 in the innovative medicine segment for intracellular, partially offset by the impact of ta… Report 21:57 deploying approximately 4.7 billion or 18.3% of sales, which includes $1 billion related t… Report 22:05 In Report 22:06 process, research and development impairment costs of $339 million in the quarter is relat… Report 22:26 with the change primarily driven by the proposed talc litigation resolution and orthopedic… Report 22:45 changes in taxes. Lastly, I'll direct your attention to the box section of the slide where… Report 22:59 Now Report 23:00 let's look at the adjusted income before tax by segment for the quarter. Innovative medici… Report 23:19 biomedicine, and unfavorable product sales mix and cost of products sold. MedTech margin i… Report 23:39 enterprise, as a percentage of sales, decreased from 35.2% to 30.2%. This concludes the sa… Report